Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.

NCT00945282 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Infection, Human Immunodeficiency Virus

Interventions

DRUG: GSK2248761
DRUG: Lopinavir/ritonavir
DRUG: HAART
DRUG: Placebo
DRUG: GSK2248761

Sponsor

ViiV Healthcare

Collaborators

[object Object]